Urol. praxi. 2026;27(2):111-114 | DOI: 10.36290/uro.2025.054
Drug interactions in the therapy of bladder cancer
- Nemocnice AGEL Valašské Meziříčí
The rapid development of oncological therapies is accompanied by an increasing incidence of drug interactions, which can significantly affect both the safety and efficacy of treatment. Most oncology patients suffer from additional chronic conditions, and due to age and comorbidities, this often leads to polypharmacy. As a result, the risk of interactions increases not only between prescribed medications, but also with over-the-counter products, dietary supplements, herbal preparations, or certain foods. Drug interactions in oncology may be both pharmacokinetic and pharmacodynamic, and can manifest as reduced therapeutic efficacy or an increased risk of toxicity. Timely identification of potential interactions is essential for optimizing treatment and minimizing risks, particularly in oncology patients. A clinical pharmacist or clinical pharmacologist can make a significant contribution to the proper evaluation and interpretation of drug interactions in individual patients.
Keywords: drug interaction, bladder cancer, inhibitor, inducer, clinical pharmacy.
Received: May 30, 2025; Revised: July 14, 2025; Accepted: July 16, 2025; Prepublished online: July 16, 2025; Published: June 10, 2026 Show citation
References
- National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer [Internet]. Version 1.2024. Plymouth Meeting (PA): National Comprehensive Cancer Network; 2024 [cited 2025 Apr 18]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf.
- Masarykův onkologický ústav. O nádorech močového měchýře [Internet]. Brno: Masarykův onkologický ústav; [cited 2025 Apr 18]. Available from: https://www.linkos.cz/pacient-a-rodina/onkologicke-diagnozy/nadory-ledviny-a-mocoveho-mechyre-c64-c67/o-nadorech-mocoveho-mechyre/.
- Česká urologická společnost. Nádory močového měchýře [Internet]. Praha: Česká urologická společnost; [cited 2025 Apr 18]. Available from: https://www.cus.cz/pro-pacienty/diagnozy/nadory-mocoveho-mechyre/.
- Květina J, Grundmann M. Farmakologické interakce. Farmakoterapie a revmatologie [Internet]. 2003;1:17-21 [cited 2025 Apr 18]. Available from: https://www.solen.cz/pdfs/far/2003/01/04.pdf.
Go to original source... - Russ K, Vaňková T. Lékové interakce - rizika u pacientů s polypragmazií. Časopis lékařů českých [Internet]. 2024;163(1):9-17 [cited 2025 Apr 18]. Available from: https://www.prolekare.cz/casopisy/casopis-lekaru-ceskych/2024-1-28/lekove-interakce-rizika-u-pacientu-s-polypragmazii-137215.
- Kozáková Š, Goněc R, Rychlíčková J, et al. Nejčastější lékové interakce u protinádorových léčiv. Onkologie [Internet]. 2018;12(6):283-286 [cited 2025 Apr 18]. Available from: https://www.onkologiecs.cz/pdfs/xon/2018/06/06.pdf. Go to original source...
- Součková L, Rychlíčková J. Lékové interakce - definice, rozdělení, význam. In: Rychlíčková J, Součková L, editors. Vybrané kapitoly z klinické farmakologie [Internet]. Brno: Masarykova univerzita; 2023 [cited 2025 Apr 27]. Available from: https://is.muni.cz/do/rect/el/estud/lf/js23/klinicka-farmakologie/web/pages/03_01_definice_rozdeleni.html.
- Holý J, Pešková M. Lékové interakce a současná klinická praxe. Kardiologická revue - Interní medicína [Internet]. 2015;17(1):70-5 [cited 2025 May 27]. Available from: https://www.kardiologickarevue.cz/pdf?id=51704.
- Vlček T, Topinková M, Ficková D. Role P-glykoproteinového transportu v klinicky významných lékových interakcích. Remedia [Internet]. 2009;19(4):266-270 [cited 2025 May 7]. Available from: https://www.remedia.cz/rubriky/klinicka-farmakologie-a-farmacie/role-p-glykoproteinoveho-transportu-v-klinicky-vyznamnych-lekovych-interakcich-974/
- Pechandová K, Buzková H, Slanař O, et al. Efluxní transmembránový transportér - P-glykoprotein. Klinická biochemie a metabolismus [Internet]. 2006;14(4):196-201 [cited 2025 May 7]. Available from: https://nts.prolekare.cz/cls/odkazy/kbm0604_196.pdf. Go to original source...
- Kalliokoski A, Niemi M. Organic Anion Transporting Polypeptides: Pharmacokinetic, Pharmacogenetic and Clinical Aspects. Br J Pharmacol [Internet]. 2009;158(3):693-705 [cited 2025 May 7]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3996503/. Go to original source...
- University of Washington. Drug Interaction Database [Internet]. [cited 2025 May 7]. Available from: https://www.drug-interactions.org.
- Hakkola J, Hukkanen J, Turpeinen M, et al. Inhibition and induction of CYP enzymes in humans: an update. Arch Toxicol [Internet]. 2020;94(11):3671-3722 [cited 2025 May 7]. Available from: https://link.springer.com/article/10.1007/s00204-020-02936-7. Go to original source...
- Weitschies W, Mönkeberg C, Abraham I, et al. Influence of inhibitors and inducers of transport proteins on pharmacokinetics. In: Handbook of Experimental Pharmacology [Internet]. 2021;266:309-345 [cited 2025 May 7]. Available from: https://link.springer.com/chapter/10.1007/164_2020_366.
- U.S. Food and Drug Administration. Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers [Internet]. [cited 2025 May 7]. Available from: https://www.fda.gov/.
- Vakciny.net. SOUHRN ÚDAJŮ O PŘÍPRAVKU - BCG vakcína SSI [Internet]. [cited 2025 May 8]. Available from: https://www.vakciny.net/object?id=215.
- National Cancer Institute. Bladder Cancer Treatment (PDQ®) - Health Professional Version [Internet]. Bethesda (MD): National Cancer Institute; 2024 [cited 2025 May 8]. Available from: https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq.
- Stumpfová A. Nežádoucí účinky methotrexátu při podávání nízkých dávek. Dermatol. pro praxi. 2024;18(4):172-176. Go to original source...
- Lexicomp. Methotrexate: Drug information. In: UpToDate [Internet]. Waltham (MA): Wolters Kluwer; c2025 [cited 2025 May 27]. Available from: https://www.uptodate.com/contents/methotrexate-drug-information.